Stock screener

TARS

Conviction 30HealthcareScan · Mon, Aug 10, 2026
TARS$67.79+4.63%
ResistanceSupportVol 14Insider sell
63 bars
2
Vol MA14 815.48K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Tarsus Pharmaceuticals, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.tarsusrx.com ↗
Price67.79
Change+4.63%
Gap-0.03%
Rel volume0.98×
Avg volume1M
Avg $ vol59.64M
SMA 2059.86
SMA 5061.37
SMA 20068.40
Price vs 50+10.47%
Price vs 200-0.89%
MA stackmixed
50/200 cross—
Supertrendup · 55.35
RSI (14)65
MACD hist1.03
MACD crossbull · 7d
Stoch %K / %D98 / 88
ADX (14)19
+DI / −DI25 / 14
RSI divergence—
MACD divergence—
ATR %+5.26%
ADR %5.25%
52w high82.51
52w low47.85
From 52w high-17.84%
Above 52w low+41.67%
New 52w highNo
SqueezeOff
Bollinger width19.97%
%B1.16
Donchian pos98.51%
Donchian high68.00
Donchian low53.89
AVWAP (52w high)66.38
vs AVWAP high+2.12%
AVWAP (52w low)65.31
vs AVWAP low+3.79%
OBV trendUp
Chaikin MF (20)0.16
Today vs 20d0.98×
Avg vol (14d)815.48K
Avg vol (20d)1M
Avg $ vol (20d)59.64M
Market cap2.97B
RS 3m (vs SPY)-4.40%
RS 6m (vs SPY)-9.60%
RS line new highNo
Trend template3/8
Technical rank61.6
1 week+10.55%
1 month+16.60%
3 months+10.75%
6 months+4.91%
1 year+41.38%
YTD-16.07%
P/E-44.79
P/B8.58
P/S6.59
P/FCF-133.34
EPS-1.59
Div yield—
ROE-19.16%
ROA-10.87%
Debt/Eq0.21
Current3.20
EV/EBITDA—
Gross margin—
Net margin-14.72%
Rev growth146.71%
EPS growth42.52%
Price target95.29
Target upside40.57%
Analyst ratingBuy
Institutional109.77%
Ent. value2.84B
Revenue173.91M
Net income-18.55M
Gross profit—
Free cash flow-22.31M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out43.02M
Employees370
ListedFri, Oct 16, 2020
Free float36.67M
Float %86.2%
Short interest5.78M
Days to cover3.2d
Short volume60.2%
Squeeze score61 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.43 vs −$0.21
Last surprise-104.8% miss
Setup gradeD
Conviction30 / 100
Pattern quality—
Tech rank61.6 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance70.99
Support54.57
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Signal lifecycle

How this symbol has moved through the lanes across 46 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.

  1. Setting up
    Jun 22
    1 scan
  2. Breaking out now
    Jun 23
    1 scan

Congress activity

Disclosed STOCK Act trades in TARS

All disclosures →
No recent disclosed trades by Congress in TARS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in TARS · 10 buys

InsiderSideShares
CHAUDHURI BHASKAR
Director · Stock Option (right to buy) · 2026-06-25
Grant3.84K
CHAUDHURI BHASKAR
Director · Restricted Stock Units · 2026-06-25
Grant2.42K
Goldberg Andrew D.
Director · Stock Option (right to buy) · 2026-06-25
Grant3.84K
Goldberg Andrew D.
Director · Restricted Stock Units · 2026-06-25
Grant2.42K
Goodrich Katherine
Director · Stock Option (right to buy) · 2026-06-25
Grant3.84K
Goodrich Katherine
Director · Restricted Stock Units · 2026-06-25
Grant2.42K
LINK WILLIAM J PHD
Director · Stock Option (right to buy) · 2026-06-25
Grant3.84K
LINK WILLIAM J PHD
Director · Restricted Stock Units · 2026-06-25
Grant2.42K
LINK WILLIAM J PHD
Director · Restricted Stock Units · 2026-06-25
Grant806
Morrison Scott W
Director · Stock Option (right to buy) · 2026-06-25
Grant3.84K

SEC filings

EDGAR filings in TARS · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.